BDX

Business Context and Reporting Period

Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-Q (Quarterly Report)
Reporting Period: Three months ended December 31, 2005 (First Quarter of Fiscal 2006)
Business Overview: BD is a medical technology company operating through three segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells medical supplies, devices, laboratory equipment, and diagnostic products globally.

Key Financial Metrics

Note: Total debt calculated as Short-term debt ($405,652) + Long-term debt ($958,885) as of Dec 31, 2005.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 10% year-over-year, driven by volume increases of approximately 10%. This growth was partially offset by a 1% unfavorable impact from foreign currency translation.
• Profitability: Operating income rose 20% to $301 million. Gross profit margin improved by 140 basis points to 52.2%, attributed to higher sales of high-margin products (insulin delivery, immunization, safety-engineered devices) and productivity gains, which offset higher raw material costs.
• Share-Based Compensation: Expense increased significantly to $34.6 million from $11.6 million in the prior year, primarily due to new grant structures with shorter vesting periods.
• Cash Flow: Operating cash flow decreased to $171 million from $264 million. This reduction was primarily due to a $127 million cash contribution to the company's pension obligation.
• Segment Performance:
  • Medical: Revenue up 11%; Operating income up 31%.
  • Diagnostics: Revenue up 7%; Operating income up 18%.
  • Biosciences: Revenue up 10%; Operating income up 26%.

Guidance, Outlook, and Risks

• Acquisition: On January 9, 2006, BD agreed to acquire GeneOhm Sciences, Inc. for approximately $230 million plus contingent payments. The deal is expected to close in Q2 2006. Management estimates the acquisition will be dilutive to EPS by 1 cent in Q2 and 7 cents for the full year, plus an in-process R&D charge of 20-25 cents per share.
• Full Year Outlook (Fiscal 2006):
  • Gross Margin: Expected to improve by approximately 50 basis points (excluding acquisition impact).
  • Selling & Admin Expenses: Expected to decrease by 50-60 basis points as a percentage of revenue.
  • R&D Expenses: Expected to increase 12-13%.
  • Capital Spending: Expected to be in the $400 million range.
  • Tax Rate: Expected to be approximately 26% for the full year.
• Capital Allocation: The company repurchased $101 million of common stock in the quarter. Approximately $1.3 billion of foreign earnings is planned for repatriation in fiscal 2006.
• Risks: Key risks include foreign currency fluctuations, raw material cost volatility (resins), healthcare cost containment initiatives, competition from new insulin delivery methods (inhaled insulin), and potential litigation outcomes (including antitrust class actions).

Investor Verification Checklist

• Acquisition Impact: Verify the final closing terms of the GeneOhm Sciences acquisition and the specific timing of the in-process R&D charge.
• Pension Funding: Confirm the sustainability of operating cash flows given the $150 million discretionary pension contribution made in the quarter.
• Share-Based Compensation: Monitor the impact of the new compensation plan (SARs and restricted stock) on future expense recognition, with $182 million remaining unrecognized.
• Antitrust Litigation: Review the status of the consolidated antitrust class action lawsuits filed in January 2006 regarding product pricing.
• Currency Hedging: Assess the effectiveness of hedging strategies given the 1-2% unfavorable currency translation impact on revenue.